Human Growth Hormone Pill Headlines
Novartis delivers strong underlying financial performance in 2011, expects 2012 sales to be in line with 2011
Fourth quarter sales rose 5% while core[1] operating income grew 17% in constant currencies (cc); full year sales up 12% cc and core operating income up 16% cc Net sales increased 4% (+5% cc) to USD 14.8 ...
Read more...
Novartis’s Gilenya Pill Reviewed by EU, U.S. After 11 Deaths
European and U.S. regulators are reviewing Novartis AG’s Gilenya pill for multiple sclerosis after reports of 11 deaths among patients who took the drug. The shares fell the most in more than five months.
Read more...
EU to Review Novartis MS Pill’s Safety After Seven Deaths
The European Medicines Agency started a review of Novartis AG’s Gilenya pill for multiple sclerosis after seven unexplained deaths among patients after beginning treatment.
Read more...
Novartis’s Gilenya MS Pill Reviewed by EU, U.S. After 11 Deaths
European and U.S. regulators are reviewing Novartis AG’s Gilenya pill for multiple sclerosis after reports of 11 deaths among patients who took the drug. The shares fell the most in almost three months.
Read more...
Google Drug Sales Settlement Involved Evidence Obtained in Sting Operation
Google’s $500 million settlement with the U.S. government over allegations the company aided illegal online drug sales involved evidence the government obtained during a sting operation, The Wall Street Journal reports.
Read more...
|